^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Guardant360 Response™

    Company:
    Guardant Health
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: C3 – Early Trials

    [HER-2 exon 20 insertion-Non Small Cell Lung Cancer-poziotinib]

    Source:
    AACR 2022
    Test:

    Guardant360® CDx, Guardant360 Response™

    Title:
    3400 / 6 - Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
    Published date:
    03/09/2022
    Excerpt:
    23 patients with tumor tissue confirmed NSCLC harboring HER2 exon 20 insertion mutations were studied….15 of the 16 (94%) patients demonstrated a decrease in mVAF at C3D1 compared to the mVAF at baseline. 12 of 15 patients demonstrated an >50% reduction in mVAF at C3D1, with 7 of the 12 patients showing >95% reduction in mVAF at C3D1 with clinical outcomes of 5 PRs, 1 non-CR/non-PD and 1 SD....Baseline plasma ctDNA genotyping correlated with tumor tissue based NGS in an NSCLC patient population with HER2 mutations. Poziotinib treatment resulted in mVAF reduction, which correlated with clinical response per RECIST1.1.